Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice
Open Access

Achieving and sustaining herd immunity to SARS-CoV-2

Shelly Bolotin, Sarah Wilson and Michelle Murti
CMAJ July 19, 2021 193 (28) E1089; DOI: https://doi.org/10.1503/cmaj.210892
Shelly Bolotin
Public Health Ontario, and Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Wilson
Public Health Ontario, and Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Murti
Public Health Ontario, and Dalla Lana School of Public Health, University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Herd immunity provides indirect protection to people who are susceptible to an infectious disease

The herd immunity threshold is the minimum proportion of the population that must be immune to an infectious disease, usually due to vaccination, for the incidence of the disease to remain stable or decrease.1

The herd immunity threshold correlates with the infectiousness of the pathogen

The herd immunity threshold for measles, one of the most infectious diseases, is about 94%.1 For SARS-CoV-2 variants of concern, such as B.1.1.7 (Alpha), the threshold is about 80%2 and it may be higher for newly emerging variants like B.1.617.2 (Delta).3

Effective vaccines with lasting protection are essential for achieving herd immunity

Vaccines are not perfect, and some vaccinated people can still become infected and transmit SARS-CoV-2.4 People who are immunosuppressed may not mount an adequate immune response. Outbreaks may occur despite high vaccine coverage in the population. Effectiveness varies by type of vaccine, number of doses administered and the particular SARS-CoV-2 variant in circulation. Based on estimates of the effectiveness of 2 vaccine doses against symptomatic infection with B.1.1.7 (Alpha) in Ontario (90% effectiveness), nearly 90% vaccine coverage in the population may be required for herd immunity.5 Increases in the prevalence of more infectious variants, and reduced vaccine effectiveness against them, would require even higher coverage. The duration of immunity from infection or vaccination is currently unknown.4

Vaccine hesitancy and structural barriers to vaccination may threaten herd immunity

High and even vaccine coverage is needed to achieve herd immunity. Achieving sufficient vaccine coverage depends on addressing vaccine hesitancy and barriers to vaccination that may result in pockets of susceptibility.

Maintaining herd immunity requires sustained effort

Maintaining herd immunity will depend on vaccines being effective against variants, addressing barriers to vaccination, and sustaining coverage if repeat vaccination is required and as the population changes (e.g., due to births, immigration). Even if herd immunity is not achieved, high vaccine coverage will substantially reduce rates of morbidity and mortality, and lessen the burden of COVID-19 on Canada’s health care systems.

Footnotes

  • Competing interests: Shelly Bolotin reports funding from the Canadian Institutes of Health Research, the Canadian Immunization Research Network, the COVID-19 Immunity Task Force and the Public Health Agency of Canada, outside the submitted work. She is a member of the Canadian Immunization Research Network Management Committee, COVID-19 Immunity Task Force Leadership Group. The authors are employees of Public Health Ontario; this organization paid for the article processing fees. No other competing interests were declared.

  • This article has been peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Vynnycky E,
    2. White RG
    . An introduction to infectious disease modelling. Oxford (UK): Oxford University Press; 2010.
  2. ↵
    1. Hodgson D,
    2. Flasche S,
    3. Jit M,
    4. et al.
    Centre for Mathematical Modelling of Infectious Disease (CMMID) COVID-19 Working Group. The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Euro Surveill 2021;26: 2100428.
    OpenUrl
  3. ↵
    3 June 2021 risk assessment for SARS-CoV-2 variant: Delta (VOC-21APR-02, B.1.617.2). London (UK): Public Health England; 2021. Available: https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-of-concern-variant-risk-assessments (accessed 2021 June 8).
  4. ↵
    1. Phillips N
    . The coronavirus is here to stay — here’s what that means. Nature 2021;590:382–4.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Chung H,
    2. He S,
    3. Nasreen S,
    4. et al
    . Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada. medRxiv 2021 May 28. doi: 10.1101/2021.05.24.21257744.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 193 (28)
CMAJ
Vol. 193, Issue 28
19 Jul 2021
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Achieving and sustaining herd immunity to SARS-CoV-2
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Achieving and sustaining herd immunity to SARS-CoV-2
Shelly Bolotin, Sarah Wilson, Michelle Murti
CMAJ Jul 2021, 193 (28) E1089; DOI: 10.1503/cmaj.210892

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Achieving and sustaining herd immunity to SARS-CoV-2
Shelly Bolotin, Sarah Wilson, Michelle Murti
CMAJ Jul 2021, 193 (28) E1089; DOI: 10.1503/cmaj.210892
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Herd immunity provides indirect protection to people who are susceptible to an infectious disease
    • The herd immunity threshold correlates with the infectiousness of the pathogen
    • Effective vaccines with lasting protection are essential for achieving herd immunity
    • Vaccine hesitancy and structural barriers to vaccination may threaten herd immunity
    • Maintaining herd immunity requires sustained effort
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Atteinte et maintien de l’immunité collective contre le SRAS-CoV-2
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Endometrial osseous metaplasia with secondary infertility
  • Bell palsy
  • The monkeypox virus
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Infectious diseases: COVID-19
    • Public health
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire